HannaH NCT and PrefHer NCT studies validated the subcutaneous H s.c. formulation of trastuzumab as effective and safe as intravenous H i.v. and highly preferred by patients in early breast cancer.The present randomised MetaspHer trial NCT is the first study assessing patient s preference in metastatic setting.
Apr 01 2017 Background. The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous s.c. versus intravenous i.v. formulation of rituximab given with chemotherapy in previously untreated patients with CD20 diffuse large B cell lymphoma DLBCL or follicular lymphoma FL .
Patient preference for intravenous or subcutaneous heparin in the treatment of deep venous thrombosis was assessed in a randomized cross over study. Twenty patients with venographically proven deep venous thrombosis were randomized to receive subcutaneous or intravenous heparin for 3 days followed by 3 days of the other treatment. Discomfort at the
Sep 01 2012 However more patients had serious adverse events in the subcutaneous group 62 21 of 297 patients than in the intravenous group 37 12 of 298 the difference was mainly attributable to infections and infestations 24 8 1 in the subcutaneous group vs 13 4 4 in the intravenous group . Four adverse events led to death one in the
This two stage phase IB study investigated the pharmacokinetics and safety of subcutaneous SC versus intravenous IV administration of rituximab as maintenance therapy in follicular lymphoma. Patients and Methods In stage 1 dose finding 124 patients who responded to rituximab induction were randomly
Sep 01 2013 Confirmed advantages of subcutaneous trastuzumab administration include improved patient convenience injection time less than 5 min vs 30–90 min for intravenous administration 13 which is important in long term or single agent trastuzumab therapy and reduced use of hospital resources and the time of health care professionals.14 15 16 20
Jul 06 2015 Background Intravenous IV intramuscular IM and subcutaneous SC are the three most frequently used injection routes in medication administration. Comparative studies of SC versus IV IM versus IV or IM versus SC have been sporadically conducted and some new findings are completely different from the dosage recommendation as described
Intravenous versus subcutaneous route pharmacokinetics of paracetamol acetaminophen in palliative care patients study protocol for a randomized trial ParaSCIVPallia Marine Vernant1 Marie Lepoupet2 Christian Creveuil4 Antoine Alix3 Charlotte Gourio3 Laure Peyro Saint Paul4 Veronique Lelong Boulouard4 and Cyril
Patients preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2 positive early breast cancer final analysis of 488 patients in the international randomized two cohort PrefHer study.
Feb 11 2019 Patients preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2 positive early breast cancer final analysis of 488 patients in the international randomized two cohort PrefHer study. Ann Oncol 25 1979–87. Google Scholar Roche Canada 2018a .
More oncology biologics are becoming available for subcutaneous sc. administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc. versus intravenous administration of approved cancer therapies and identify outcomes favoring either administration route.
PrefHer study was designed to assess patients’ preferences for trastuzumab SC or IV in the adjuvant breast cancer setting. Patients with HER2 positive early breast cancer were randomised to receive 4 cycles of trastuzumab SC followed by 4
32 rows Apr 19 2021 Among patients who preferred intravenous infusions the main advantages were the lower treatment frequency the presence of healthcare professionals and the resulting feelings of safety. Many patients had experience of either intravenous or subcutaneous treatment and tended to prefer their current treatment option.
Sep 04 2013 Of the 124 patients in each arm 117 from the subcutaneous first group and 119 in the intravenous first group were included in the intent to treat population. In order to determine patient preference for subcutaneous vs intravenous administration the researchers interviewed patients at baseline and after both treatments.
Preference for Subcutaneous Injection Versus Intravenous Infusion The preference for a subcutaneous injection device was 41.2 . The preference for an intravenous delivery was 36.9 . Finally 21.9 of respondents didn’t know. Table 1 presents the distribution of preferences according to gender age group YFD and past experience of
May 01 2020 The proportion of patients with very good partial response or better was similar between the subcutaneous and intravenous groups 50 19 vs 44 17 odds ratio 1 16 95 CI 0 73–1 85 p=0 53 . Complete response or better was also similar between the subcutaneous and intravenous groups five 2 patients vs seven 3 table 2 . The
Dec 13 2019 Pivot X Gligorov J Müller V et al. Patients preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2 positive early breast cancer
On Sunday 2 June 2019 during the annual American Society of Clinical Oncology ASCO meeting in Chicago US our Steering Committee member Maria Victoria Mateos from University of Salamanca Salamanca ES presented data from the COLUMBA trial NCT . 1. COLUMBA is a phase III trial designed to show that the administration of daratumumab
Jun 01 2018 Among the general patient population intravenous opioid doses were reduced by 84 during the intervention period 0.06 vs 0.39 doses per patient day P < .001 and combined doses of parenteral opioids given by either intravenous or subcutaneous route were reduced by 55 0.18 vs 0.39 doses per patient day P < .001 Figure 1A .
Dec 03 2015 To improve patient convenience and to reduce healthcare resource burden a subcutaneous SC formulation of rituximab has been developed and has been shown to be clinically comparable to intravenous IV rituximab. The aim of this study was to evaluate patient preference for rituximab IV or SC administration. Methods
Sep 21 2016 PURPOSE To assess patient preference for oral versus intravenous i.v. palliative chemotherapy CT . A strong preference would be an important quality of life issue. PATIENTS AND METHODS A structured interviewer administered scenario based questionnaire evaluated incurable cancer patients who would be likely to receive palliative CT in the future.
Jul 25 2011 Patients preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2 positive early breast cancer final analysis of 488 patients in the international randomized two cohort PrefHer study. Ann Oncol. 2014 Oct25 10 1979 1987. doi 10.1093/annonc/mdu364. Epub 2014 Jul 28.
Feb 04 2020 Among palliative care PC patients who are administered paracetamol the subcutaneous SC route is often an alternative to the intravenous IV route. Yet pharmacological and clinical data on whether these are equivalent pharmacokinetically are lacking. Many French palliative teams are now empirically using paracetamol by the SC route
Patients preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2 positive early breast cancer final analysis of 488 patients in the international randomized two cohort
Intravenous Versus Subcutaneous Dosing of Epoetin Alfa iu Hemodialysis Patients Emil P. Paganini MD Joseph W. Eschbach MD J. Michael Lazarus MD Thirteen to 16 weeks after patients were changed from IV three times per week to SC three times per week treatment the Epoetin alfa requirement was reduced by 18.5 i 3.8 P < 0.001 n = 72
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
No.18,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
